Regado Biosciences, Inc., a biopharmaceutical company, recently announced that the United States Patent and Trademark Office (USPTO) has issued an important patent that expands protection of Regado's core technology platform while broadening the range of aptamer-based therapies upon which Regado may base future products.

Regado's current drug development programmes, including its lead REG1 Anticoagulation System, consist of an aptamer-based pharmacologic drug paired with a specific control agent. US patent 8,586,524, the newest issuance in the "Modulators of Pharmacologic Agents" patent family, describes the classes of molecules that can be developed as control agents to modulate aptamer activity in the body. Specifically, '524 extends coverage beyond nucleic acid-based modulators to now include peptide-, polypeptide- and protein-based control agents for the modulation of aptamer-based anticoagulants.

Christopher Rusconi, Regado's chief scientific officer, stated, "Regado is committed to continuously broadening our patent position and leveraging intellectual property to strengthen our novel technology platform. As we continue to advance REG1 through our pivotal phase III REGULATE-PCI trial and closer to potential commercialization, the '524 patent protects Regado from potential competing aptamer-based anticoagulants designed to employ peptide or protein-based modulators. The patent also expands the future development possibilities for anticoagulant products, allowing us to maintain our leadership position in this space, which is critical for attracting potential development partners."

US patent 8,586,524 builds upon US patents 8,283,330 and 7,300,992, which cover a spectrum of oligonucleotide and oligonucleotide-related modulators designed to target anticoagulants specifically ('330), as well as aptamers directed against any other type of molecular target ('992).

Regado Biosciences, Inc., is focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.